- Earth Science Tech is looking to expand its line of work through two wholly owned subsidiaries
- Its subsidiaries focus on R&D and product development
- The company recently outlined a five-year marketing and manufacturing plan
Earth Science Tech Inc. (OTCQB: ETST) is an aspiring biotech company engaged in the development of cannabinoid-based products and the research and development of medical devices and pharmaceuticals. Using the supercritical CO2 liquid extraction, isolation and micron filtration process, the company manufactures 100 percent natural CBD oil. This pure, easily digested, rich CBD hemp oil is unique to the nutraceuticals industry and represents a significant asset to ETST.
Earth Science Tech is currently looking to expand its operations in the areas of CBD product development and R&D of medical devices and pharmaceuticals through its two wholly owned subsidiaries: Earth Science Pharma Inc. and Cannabis Therapeutics Inc.
Earth Science Pharma Inc. is focused on the research and development of low-cost medical devices and vaccines that benefit women’s health. The company recently introduced its first medical device, MSN-2, a home kit designed for the detection of STIs such as chlamydia. The company has named this kit Hygee. By circumventing the need for laboratory analysis, ETST anticipates that the kit will empower women across the world, giving them a low-cost, noninvasive method to meet their diagnostic health care needs (http://ibn.fm/HROu1).
Aside from Earth Science Pharma’s innovations in the diagnostic health care space, ETST has another subsidiary operating in the burgeoning cannabis industry. Cannabis Therapeutics Inc. is committed to the research and development of medicinal cannabidiol. The company also possesses a provisional application patent for a CBD product that can be used for developing medications to treat breast and ovarian cancers.
ETST recently filed a 10-K annual report with the SEC that included an outline of the company’s five-year expansion plan for manufacturing and marketing its CBD products (http://ibn.fm/JY9mT). The plan includes information about the company’s strategic preparations to scale up the production of its CBD oil, introduce new products and make its innovative hemp products available worldwide (http://ibn.fm/5OZ0R).
Earth Science Tech has teamed up with the University of Central Oklahoma to conduct research and development projects. In addition, studies from the DV Biologics Laboratory scientifically support and advance the health care benefits of the company’s high-grade hemp CBD oil. These studies show positive results regarding breast cancer and immune cells to support that ETST’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive-result case studies conducted through key health organizations.
“Our CBD-rich hemp oil does not contain any synthetic cannabinoids and is not an isolate,” the SEC report noted. “It contains everything that is naturally occurring in the original industrial hemp plant. With our high-quality, CBD-rich hemp oil you benefit from the natural interaction of phytonutrients in their balanced wide-ranging form that may offer the most benefit for overall wellness.” The report further noted that the company’s “commercialized, CBD-based product line, High-Grade Full Spectrum Cannabinoids, offers seven distinct cannabinoids maximizing all the therapeutic benefits the industrial hemp plant has to offer.”
Through the innovative products offered by its two wholly owned subsidiaries, ETST is well-positioned to stay abreast of current trends in multiple markets.
For more information, visit the company’s website at www.EarthScienceTech.com
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
